Subscribe
pimpic-shutterstock-com
pimpic / Shutterstock.com
18 April 2016Asia

Indian drug makers end generic bids

Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb (BMS).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.

More on this story

Asia
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
2 March 2016   Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.
Asia
India should remain on 301 ‘Priority Watch List’, says PhRMA
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.
Asia
Indian Pharmaceutical Alliance drops Sovaldi opposition
16 September 2015   The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent